San Jose, United States
Nodexus Inc., founded in 2014, is making significant strides in the biopharma and biotechnology sectors from its headquarters in the United States. The company's core mission, as captured in their slogan, is "democratizing access to live single cells for applications including gene editing, drug development, and more."
Endorsed by its affiliation with prestigious institutions like UC Berkeley and Stanford StartX, Nodexus aims to make complex single-cell workflows more accessible, spanning fields from gene editing to cancer biology and agriculture. This ambition has been substantiated by the company's ability to attract substantial investment support.
In its last funding round, Nodexus raised a noteworthy $30.00M in a Series A round on 01 December 2021, with backing from prominent investors RA Capital Management and Section 32. This capital injection underscores investor confidence and positions Nodexus Inc. as a compelling opportunity in the rapidly evolving biotech landscape.
